

Vale announces agreement with the United States Securities and Exchange Commission

Rio de Janeiro, March 28, 2023 - Vale S.A. ("Vale" or the "Company") informs that it has entered into an agreement with the United States Securities and Exchange Commission ("SEC"). The agreement will terminate a lawsuit filed by the SEC against the Company in April 2022 and will be effective once ratified by the United States District Court for the Eastern District of New York. Under the agreement, without admitting or denying the settled claims, Vale will make payments totaling US\$ 55.9 million to the SEC. In addition, the SEC will not oppose Vale's motion to dismiss all claims that the Company acted with fraudulent or reckless intent regarding its disclosures. Vale continues with its commitment to remediate and repair the damage caused by the dam collapse in Brumadinho in 2019.

Gustavo Duarte Pimenta Executive Vice President, Finance and Investor Relations

> For further information, please contact: Vale.RI@vale.com Ivan Fadel: ivan.fadel@vale.com Luciana Oliveti: luciana.oliveti@vale.com Mariana Rocha: mariana.rocha@vale.com Samir Bassil: samir.bassil@vale.com

This press release may include statements that present Vale's expectations about future events or results. All statements, when based upon expectations about the future, involve various risks and uncertainties. Vale cannot guarantee that such statements will prove correct. These risks and uncertainties include factors related to the following: (a) the countries where we operate, especially Brazil and Canada; (b) the global economy; (c) the capital markets; (d) the mining and metals prices and their dependence on global industrial production, which is cyclical by nature; and (e) global competition in the markets in which Vale operates. To obtain further information on factors that may lead to results different from those forecast by Vale, please consult the reports Vale files with the U.S. Securities and Exchange Commission (SEC), the Brazilian Comissão de Valores Mobiliários (CVM) and in particular the factors discussed under "Forward-Looking Statements" and "Risk Factors" in Vale's annual report on Form 20-F.